Lazzaro Spallanzani National Institute for Infectious Diseases

The Lazzaro Spallanzani National Institute for Infectious Diseases (Italian: Istituto nazionale per le malattie infettive "L. Spallanzani") is an infectious disease hospital in the Italian city of Rome. The institute is named for the eighteenth-century Italian biologist Lazzaro Spallanzani.

It is the Italian national reference center for Ebola patients.[1]

During the COVID-19 pandemic, the Spallanzani Institute was the first research centre in Europe to isolate the genomic sequence of SARS-CoV-2 and upload it to GenBank.[2] The team was composed of Maria Rosaria Capobianchi, Francesca Colavita, and Concetta Castilletti.[3]

The institute is working with biotech company ReiThera to test a COVID-19 vaccine candidate called GRAd-COV2, which is based on a modified chimpanzee adenovirus vector.[4]

References
  1. "Nurse in Italy tests positive for Ebola; was in Sierra Leone". U-T San Diego. Retrieved 13 May 2015.
  2. "Una speranza dall'Istituto Spallanzani di Roma: "Abbiamo isolato il coronavirus"". La Stampa (in Italian). Retrieved 2 February 2020.
  3. "Le tre ricercatrici che hanno isolato il Coronavirus allo Spallanzani di Roma". Sky TG24 (in Italian). Retrieved 2 February 2020.
  4. "New ReiThera vaccine safe, response peak at 4 wks". ANSA. 5 January 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.